---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-040503"
form_type: "8-K"
ticker: "IMNM"
cik: "0001472012"
company_name: "Immunome Inc."
filed_at: "2024-03-28T23:59:59+00:00"
generated_at: "2026-06-04T06:03:19.535130+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Immunome posts FY2023 net loss of $106.8M; cash $138.1M, AL102 Phase 3 data due Q1 2025

## Summary
- Net loss $106.8M ($5.38 per share) for FY2023; cash and equivalents $138.1M as of Dec 31, 2023 (prior to Feb 2024 $230M offering).
- AL102 Phase 3 RINGSIDE topline data expected Q1 2025; IND filings for IM-1021 and IM-3050 expected Q1 2025.
- Closed acquisition of AL102 from Ayala (Mar 2024) and licensed IM-1021 from Zentalis (Jan 2024).
- Completed $230M underwritten offering in Feb 2024, extending cash runway into 2026.
- R&D expenses $23.1M, IPR&D $80.8M, G&A $19.7M for FY2023.

## SEC filing metadata
- accession: 0001104659-24-040503
- form_type: 8-K
- ticker: IMNM
- cik: 0001472012
- company_name: Immunome Inc.
- filed_at: 2024-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/0001104659-24-040503-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/tm2410047d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-040503
- JSON: https://secwatch.observer/filing/0001104659-24-040503.json
- Plain text: https://secwatch.observer/filing/0001104659-24-040503.txt

## Key facts
- Earnings Releases
  Immunome Inc. reported the full-year ended December 31, 2023 results: net income $106.8 million, EPS $5.38.
  - Period: the full-year ended December 31, 2023
  - Net income: $106.8 million
  - EPS: $5.38
  - Result: reported results
  source text: Immunome reported a net loss of $106.8 million, or basic and diluted net loss per share attributable to common stockholders of $5.38, for the year ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1472012/000110465924040503/0001104659-24-040503-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.